Nov. 2, 2017—Three years ago Reece Dean, of Nashville’s Bellevue community, retired at age 69 from a career as a busy truck driver. Mary Ann, his wife, began to notice some changes in his memory and behavior since he was home more consistently.
Aug. 7, 2017—Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.
Dec. 27, 2016—Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.
Oct. 29, 2015—Vanderbilt University Medical Center has received a $9.4 million grant from the National Institute on Aging (NIA) to test the effectiveness of a transdermal nicotine patch in improving memory loss in older adults with mild cognitive impairment (MCI), a precursor to Alzheimer’s disease.
Nov. 25, 2013—Eighteen academic and administrative leaders at Vanderbilt University have been elected fellows of the American Association for the Advancement of Science (AAAS) this year.
Dec. 20, 2012—Nine Vanderbilt University faculty members named to endowed chairs were honored for outstanding academic achievements last week during a celebration at the Student Life Center. “An endowed chair is the highest academic honor that a university can bestow on its faculty,” said University Provost and Vice Chancellor for Academic Affairs Richard McCarty, Ph.D. “It’s really...
Jan. 27, 2012—This Week on VUCast, Vanderbilt’s weekly newscast highlighting research, experts, students, sports and everything Vanderbilt: · Inside A Preds coach’s deep brain stimulation surgery · How nicotine could impact memory · Why a research lab wants Vandy undergrads
Jan. 13, 2012—Wearing a nicotine patch may help improve memory loss in older adults with mild cognitive impairment, according to a study published this week by Paul Newhouse, director of the Center for Cognitive Medicine.